Claims
- 1. An isolated polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
- 2. An isolated polypeptide according to claim 2, wherein said polypeptide is at least 90% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
- 3. An isolated polypeptide according to claim 1, covalently linked amino terminally or carboxy terminally to a moiety selected from the group consisting of affinity tags, toxins, radionucleotides, enzymes and fluorophores.
- 4. A isolated polynucleotide encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
- 5. An isolated polynucleotide according to claim 4, wherein said polypeptide is at least 90% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
- 6. An isolated polynucleotide comprising the sequence of nucleotide 1 to nucleotide 1437 of SEQ ID NO:4.
- 7. An oligonucleotide probe or primer comprising at least 14 contiguous nucleotides of a polynucleotide of SEQ ID NO:4 or a sequence complementary to SEQ ID NO:4.
- 8. An expression vector comprising the following operably linked elements:
a transcription promoter; a DNA segment encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2; and a transcription terminator.
- 9. An expression vector according to claim 8, wherein said DNA segment encodes a polypeptide that is at least 90% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
- 10. An expression vector according to claim 8, wherein said DNA segment encodes a polypeptide covalently linked amino terminally or carboxy terminally to an affinity tag.
- 11. An expression vector according to claim 8, wherein said DNA segment further encodes a secretory signal sequence operably linked to said polypeptide.
- 12. A cultured cell into which has been introduced an expression vector comprising the following operably linked elements:
a transcription promoter; a DNA segment encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2; and a transcription terminator; wherein said cell expresses said polypeptide encoded by said DNA segment.
- 13. A method of producing a polypeptide comprising:
culturing a cell into which has been introduced an expression vector comprising the following operably linked elements: a transcription promoter; a DNA segment encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2; and a transcription terminator; whereby said cell expresses said polypeptide encoded by said DNA segment; and recovering said expressed polypeptide.
- 14. A pharmaceutical composition comprising a polypeptide, said polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2;
in combination with a pharmaceutically acceptable vehicle.
- 15. An antibody that specifically binds to an epitope of a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
- 16. A binding protein that specifically binds to an epitope of a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
- 17. A method for detecting a genetic abnormality in a patient, comprising:
obtaining a genetic sample from a patient; incubating the genetic sample with a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1, under conditions wherein said polynucleotide will hybridize to complementary polynucleotide sequence, to produce a first reaction product; comparing said first reaction product to a control reaction product, wherein a difference between said first reaction product and said control reaction product is indicative of a genetic abnormality in the patient.
REFERENCE TO RELATED APPLICATIONS
[0001] This application is related to Provisional Application No. 60/056,130, filed on Aug. 19, 1997. Under 35 U.S.C. §119(e) (1), this application claims benefit of said Provisional Application.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60056130 |
Aug 1997 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09137223 |
Aug 1998 |
US |
Child |
10014137 |
Dec 2001 |
US |